Lennox-Gastaut%25252525252525252525252525252525252525252525252520syndrome

# Lennox-Gastaut Syndrome ## Overview Lennox-Gastaut Syndrome (LGS) is a severe, rare form of epilepsy characterized by a combination of frequent, diverse seizure types (tonic, atonic, absence, and atypical absence), intellectual disability, and characteristic EEG patterns (slow spike-and-wave). ## Primary Indications LGS is indicated for adjunctive treatment of seizures associated with LGS in patients 2 years of age and older. Several antiepileptic drugs (AEDs) are used, often in combination. Approved agents include clobazam, rufinamide, and perampanel. Cannabidiol (Epidiolex) is also approved. Felbamate and vigabatrin have efficacy but significant safety concerns. ## Adult Dosing * **Clobazam:** Initial dose: 5 mg twice daily. Titrate by 5-10 mg every week. Usual maintenance dose: 10-20 mg twice daily (max 30 mg twice daily). * **Rufinamide:** Initial dose: 200 mg twice daily. Increase by 200 mg twice daily every week. Usual maintenance dose: 1600 mg twice daily (max 3200 mg/day in divided doses). * **Perampanel:** Initial dose: 2 mg once daily, taken at bedtime. Increase by 2 mg weekly or bi-weekly. Usual maintenance dose: 8-12 mg once daily (max 12 mg once daily). * **Cannabidiol (CBD):** Initial dose: 2.5 mg/kg twice daily. Increase by 2.5 mg/kg twice daily every week. Usual maintenance dose: 10 mg/kg twice daily (max 20 mg/kg twice daily). * **Felbamate:** (Use with extreme caution due to risk of aplastic anemia and hepatic failure) Initial dose: 15 mg/kg/day in 3-4 divided doses. Increase by 15 mg/kg/day every 2 weeks. Usual maintenance dose: 45 mg/kg/day in 3-4 divided doses (max 3600 mg/day). * **Vigabatrin:** (Use with extreme caution due to risk of irreversible visual field defects) Initial dose: 500 mg twice daily. Increase by 250 mg twice daily every 4 weeks. Usual maintenance dose: 3000 mg/day in 2-3 divided doses. Dosing is highly individualized and often requires titration based on efficacy and tolerability, guided by local protocols. ## Pediatric Dosing * **Clobazam:** Similar to adults, starting at 2.5 mg twice daily and titrating. Maximum doses may be lower depending on weight. * **Rufinamide:** Initial dose: 200 mg twice daily. Increase by 200 mg twice daily every week. Usual maintenance dose: 1600 mg twice daily (max 3200 mg/day in divided doses for patients >30 kg; max 1000 mg/day in divided doses for patients <=30 kg). * **Perampanel:** Initial dose: 0.2 mg/kg once daily at bedtime. Increase by 0.2 mg/kg weekly or bi-weekly. Usual maintenance dose: 0.4-0.8 mg/kg once daily (max 12 mg once daily). * **Cannabidiol (CBD):** Initial dose: 2.5 mg/kg twice daily. Increase by 2.5 mg/kg twice daily every week. Usual maintenance dose: 10 mg/kg twice daily (max 20 mg/kg twice daily). * **Felbamate:** (Use with extreme caution) Initial dose: 15 mg/kg/day in 3-4 divided doses. Usual maintenance dose: 45 mg/kg/day in 3-4 divided doses (max 3600 mg/day). * **Vigabatrin:** (Use with extreme caution) Initial dose: 40 mg/kg/day in 2 divided doses. Usual maintenance dose: 80-100 mg/kg/day in 2-3 divided doses (max 3000 mg/day). Dosing is highly individualized and weight-based, requiring careful titration and monitoring as per local pediatric epilepsy protocols. ## Dose Adjustments * **Hepatic Impairment:** Dose reduction may be necessary for clobazam, rufinamide, perampanel, and CBD. Consult product information. * **Renal Impairment:** Dose adjustment may be needed for rufinamide and perampanel. Consult product information. * **CYP3A4 Inhibitors/Inducers:** May affect clobazam levels. * **Other AEDs:** Consider potential drug interactions and need for dose adjustments. ## Contraindications * Hypersensitivity to the drug or its components. * Specific contraindications for certain agents, e.g., hepatic impairment for fenamate, history of suicidal behavior for perampanel. ## Adverse Effects Common adverse effects include somnolence, decreased appetite, diarrhea, fatigue, irritability, aggression, upper respiratory tract infections, and vomiting. Sedation and behavioral changes are often prominent. Serious adverse effects include suicidal behavior/ideation, hepatic failure, aplastic anemia (felbamate), visual field defects (vigabatrin), and hypersensitivity reactions. ## Key Drug Interactions * **CYP3A4 Inhibitors/Inducers:** Can alter levels of clobazam. * **Other AEDs:** Many AEDs can induce or inhibit CYP enzymes, affecting the metabolism of other AEDs or non-antiepileptic drugs. Examples include induction by carbamazepine or phenytoin, and inhibition by valproic acid. * **CNS Depressants:** Additive sedative effects with alcohol, benzodiazepines, opioids, and other sedating medications. * **Enzyme Inducers (e.g., rifampin):** May decrease efficacy of CBD. ## Monitoring * **Seizure Frequency and Type:** Regular assessment of seizure control. * **Hepatic Function:** Baseline and periodic monitoring, especially with felbamate and vigabatrin. * **Renal Function:** Baseline and periodic monitoring. * **Hematologic Parameters:** Baseline and periodic monitoring, especially with felbamate. * **Ophthalmologic Examinations:** Regular visual field testing with vigabatrin. * **Suicidal Behavior/Ideation:** Monitor for changes in mood and behavior. * **Drug Levels:** May be considered for some agents, though not routinely required for all. ## Clinical Pearls * LGS treatment is challenging and often requires polytherapy with multiple AEDs. * Dosing titration must be slow and cautious, closely monitoring for efficacy and adverse effects, especially sedation and behavioral changes. * Consider the potential for cognitive and behavioral side effects, which can be difficult to distinguish from the underlying syndrome. * Vigabatrin and felbamate are effective but carry significant risks; their use should be reserved for cases refractory to other agents and managed by specialists. * Cannabidiol (CBD) is a non-psychoactive cannabinoid that has shown efficacy as adjunctive therapy. * Ensure adequate contraception counseling for individuals of reproductive potential, as some AEDs can impact oral contraceptive efficacy. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions. Local protocols may vary.